Key points are not available for this paper at this time.
Among patients with stage I HER2+ BC, one year of adjuvant T-DM1 was associated with excellent 3-year iDFS, but was not associated with fewer CRT compared with TH.
Tolaney et al. (Wed,) studied this question.